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Haemophilia care in India is slowly progressing but the
diagnostic and management challenges continue until
optimum care for haemophilia patients become a reality
in this country. Against an anticipated severe haemophi-
lia population of more than 0.1 million, only 16000 hae-
mophilia patients are registered in the 74 Haemophilia
Chapters across the country. As per the recent WFH
Survey, 43% of the World haemophilia population live
in India, Bangladesh, Indonesia and China, out of which
only 12% is diagnosed in these countries. Additionally
these countries represent only 2% of the Worlds total fac-
tor usage. The per capita use of FVIII in India has been
shown to be 0.0075 (1IU per capita is 20000 IU FVIII per
haemophilia patient) which is approximately equal to
mean consumption of 1654 IUs per PWH against 112508
IUs per PWH in United States. Haemophilia in India is
thus a grossly under diagnosed disorder, mainly due to
lack of awareness and diagnostic facilities in this country.
Except a few Corporate Hospitals and a few Medical
Colleges in India majority of the 630 District hospitals
and Medical Colleges do not have even screening coagu-
lation facilities. Haemophilia Federation (India) has taken
wide initiatives in providing diagnostic facilities to the
PWH in this country, through various measures such as
supporting the cost of diagnosis of PWH, networking pri-
vate laboratory facilities, setting up coagulation labora-
tories in close proximity to Haemophilia Chapters,
involving faculty members of Medical Colleges in the
activities of Haemophilia Chapters and so on. Indian
Council of Medical Research has also initiated through
its Translation Research Programme several workshops
in the Laboratory diagnosis of bleeding disorders at
Mumbai and several places in East and North Eastern
parts of India. As quality control is an important exercise
in a coagulation laboratory, many of the laboratories in
India fail to establish factor and inhibitor screening
assays in their respective laboratories.
The prevalence of inhibitors in India is estimated to be
8.2–13%. Post operative inhibitors are another important
problem which our PWH is facing in India. About 30% of
PWH undergoing surgeries for various indications develop
inhibitors postoperatively. Diagnosing inhibitors, demands
specialized laboratories and expertise. The management of
PWH and inhibitors comprises several approaches invol-
ving prompt treatment of bleeding episodes, managing its
complications, preventing bleeds, and conserving and
restoring joint function. The ultimate goal of treating
PWH and inhibitors is to permanently eradicate inhibitors
by immune tolerance therapy (ITT), or by use of alterna-
tive products like rFVIIa or FEIBA. However, because of
prohibitive cost and logistics constraints many of our
PWH are not able to utilize these products. Availability of
free factors in some states of our country is a refreshing
and welcome change for PWH. Significant progress has
been made in awakening and alerting the State Govern-
ments for providing free factors to all our PWH. WFH has
contributed to haemophilia care in India through a series
of international twinning programme by initially twinning
upcoming chapters in India or institutions of repute in
India with some of the best centres in Europe and USA
leading to the development of expertise in the area of
genetic diagnosis and physical therapy.
Despite this, there are several newer challenges that the
hemophilia community will face in the coming years.
Normalization of patients’ lives as a result of improved
treatment has led to new problem areas. Malignancies spe-
cifically hepatocellular carcinoma (HCC) in HCV infected
patients and non Hodgkin’s lymphoma in HIV infected
patients are on the rise. About 25% of our patients is HCV
infected. A less common albeit potentially severely morbidCorrespondence: shrimatishetty2@gmail.com
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event is ICH. Osteoporosis in general has been considered
to be an important cause of morbidity in patients with
haemophilia and other bleeding disorders.
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